Arcturus Therapeutics Holdings Inc

NASDAQ:ARCT 4:00:00 PM EDT

23.97

+3.33 (+16.13%)

6:20:03 PM EDT: $23.95 -0.02 (-0.08%)

Products, Regulatory

Arcturus Therapeutics Gets Approval From Singapore Health Sciences Authority To Proceed With Phase 2 Study Of Arct-021 (Lunar-Cov19) Vaccine Candidate

Published: 12/28/2020 21:16 GMT

Arcturus Therapeutics Holdings Inc (ARCT) - Arcturus Therapeutics Received Approval From Singapore Health Sciences Authority to Proceed With Phase 2 Study of Arct-021 (lunar-cov19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data.
Arcturus Therapeutics Holdings Inc - Anticipate Interim Phase 2 Data in Early 2021; Targeting Global Phase 3 Study Start in Q2 2021.
Arcturus Therapeutics Holdings Inc - Phase 1/2 Data Demonstrates Favorable Tolerability.